India's snakebite crisis is a devastating issue, claiming the lives of tens of thousands annually. The impact is particularly severe in rural areas, where poor infrastructure and limited access to medical resources exacerbate the problem. A recent report by the Global Snakebite Taskforce (GST) reveals that 99% of healthcare workers in India face challenges administering antivenom, the crucial antibodies that neutralize snake venom. This is due to poor infrastructure, limited access to antivenom, and insufficient training. Delays in treatment often lead to serious complications, including amputations, surgeries, or lifelong mobility issues. Snakebites disproportionately affect poor rural communities in low and middle-income countries, with a high concentration of deaths and injuries reported in central and eastern regions. In response, India launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAPSE) in 2024, aiming to halve snakebite deaths by 2030. However, implementation has been inconsistent, and snakebites are often overlooked as a 'poor person's problem', leading to under-reporting and inadequate political will. The availability of high-quality antivenom is another major hurdle, as India currently only has antivenom for the 'big four' snake species, leaving many other poisonous species without targeted treatment. The Liana Trust, for instance, has been working to develop antidotes for species beyond the big four, but progress has been slow due to the labor-intensive and time-consuming process. To combat under-reporting, some states have made snakebites 'notifiable diseases', requiring health professionals to report cases to authorities. However, the challenge remains in ensuring that poor people receive adequate healthcare systems and that snakebite deaths are addressed with the urgency they deserve.
